Fig. 4From: Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivoEnhanced LDH release in MDA-MB-231 cells treated with AsIII combined with Tetra. After treatment with 10 μM AsIII and 4 μg/ml Tetra, alone or in combination, in the presence or absence of 0.25 μM wortmannin, for 48 h, LDH leakage was measured using the LDH-Cytotoxic test kit as described under “Materials and methods”. Significant difference between control and treatment with AsIII and Tetra, alone or in combination, are shown (†p < 0.0001 vs. control; ∫p < 0.0001 vs. AsIII alone; ♪p < 0.001 vs. Tetra). As, AsIII; Tetra, tetrandrineBack to article page